As part of the agreement, Providence will provide the necessary technology transfer for Biological E to manufacture mRNA vaccines in India, with a minimum production capacity of 600 million doses in 2022 and a target capacity of 1 billion doses.
Apart from this, Providence will also export 30 million doses to India from its existing North American capacity.
Biological E said it will be responsible for all clinical development and regulatory activities, including applying for emergency use authorisation (EUA), for the mRNA vaccine in India and other jurisdictions licensed by Biological E. However, Biological E did not disclose the financial terms of the transaction.
According to the Hyderabad-based vaccine maker, the two players have executed a term sheet for a definitive licensing and collaboration agreement that also outlines the terms for sale by Providence of up to 30 million doses of Providence’s proprietary messenger RNA vaccine to Biological E and other end-buyers.
“The mRNA platform has emerged as the front runner in delivering the first vaccines for emergency use to combat the Covid19 pandemic. Biological E. is very pleased to be able to work with Providence on its promising mRNA vaccine candidate. We hope to provide India and other countries yet another option to ramp up their efforts towards achieving herd immunity against Covid-19,” Biological E managing director Mahima Datla said.
Mahima Datla, MD, Biological E
“This sale represents the sale of all the remaining 2021 Providence production, plus a portion of the early 2022 Providence production, after accounting for the first sale of Providence vaccines to the Province of Manitoba, Canada,” Biological E said.
“This initiative is an important commitment by a Canada-based company to help India and other nations vaccinate their citizens against COVID19. Providence was founded to serve patients, and this commitment by Biological E allows us to achieve that essential goal,” said Brad Sorenson, CEO of Providence in a statement.